Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Sep 21:10:50.
doi: 10.1186/1471-2466-10-50.

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis

Ann Van den Bruel  1 , Jeannine Gailly, Mattias Neyt
Affiliations
Meta-Analysis

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis

Ann Van den Bruel et al. BMC Pulm Med. .

Abstract

Background: International guidelines recommend long-acting bronchodilators in patients who remain symptomatic despite adequate treatment with short-acting bronchodilators. The purpose of this study is to estimate the effect of tiotropium, a long-acting anticholinergic inhalant, on exacerbation and hospitalisation frequency.

Methods: Electronic databases (Medline, Embase, INAHTA, CRD databases, and the Cochrane Library) were searched for randomised controlled trials, comparing tiotropium to placebo, or other bronchodilators. Outcomes were the exacerbation frequency and hospitalisation frequency. Data were pooled using the generic inverse variance method for continuous outcomes.

Results: Nine studies reported comparisons with placebo (n = 8), ipratropium (short-acting anticholinergic inhalant, n = 1), and salmeterol (long-acting β₂-agonist inhalant, n = 1). Only two studies reported adequate concealment of allocation. Tiotropium reduces the number of exacerbations per patient year by 0.31 (95% CI 0.46- 0.17) compared to placebo, and by 0.23 (95% CI 0.31- 0.15) compared to ipratropium. A significant difference in exacerbation frequency between tiotropium and salmeterol was found (-0.16; 95% CI -0.29 - -0.03) based on approximations of the results of one study.The number of hospitalisations is reduced by 0.04 (95% CI 0.08- 0.01) per patient year compared to placebo and by 0.06 (95% CI -0.09 - -0.03) per patient year compared to ipratropium.

Conclusions: Statistically significant but clinically small effects were found for tiotropium compared to placebo and ipratropium. The comparison with salmeterol is significant for exacerbation frequency but not for hospitalisation frequency. Publication bias may be present.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of literature search.
Figure 2
Figure 2
Quality assessment of included studies.
Figure 3
Figure 3
Summary graph of meta-analyses of continuous outcomes.
Figure 4
Figure 4
Meta-analyses on exacerbation frequency.
Figure 5
Figure 5
Meta-analyses on COPD-related hospitalisation frequency.
Figure 6
Figure 6
Funnel plots of studies reporting exacerbation frequency (left) and exacerbation-related hospitalisation frequency (right).
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2007. http://www.goldcopd.org - PubMed
    1. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online) 2005. p. CD002876. - PMC - PubMed
    1. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther. 2007;20:495–502. doi: 10.1016/j.pupt.2006.02.003. - DOI - PubMed
    1. Neyt M, Van den Bruel A, Gailly J, Thiry N, Devriese S. Health Technology Assessment KCE reports 108C. Brussels: Belgian Health Care Knowledge Centre (KCE); 2009. Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: Health Technology Assessment.
    1. Schermer TRJ, Saris CGJ, van den Bosch WJHM, Chavannes NH, van Schayck CP, Dekhuijzen PNR, van Weel C. Exacerbations and associated healthcare cost in patients with COPD in general practice. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace/Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universita di Napoli, Secondo ateneo. 2006;65:133–140. - PubMed

Publication types

MeSH terms